Contribution to the issue of hepatorenal damage and failure

Česká verzia

Authors: V. Teplan
Authors place of work: Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha 1. LF UK, Praha Subkatedra nefrologie, Institut postgraduálního vzdělávání ve zdravotnictví, Praha Katedra interních oborů, LF OU, Ostrava
Published in the journal: Gastroent Hepatol 2018; 72(3): 242-250
Category:
doi: https://doi.org/10.14735/amgh2018242

Summary

Kidney and liver are the most metabolically active solid organs in the human body, helping to maintain a balanced protein, carbohydrate, lipid and energy metabolism and contributing to mineral and water stability and hormonal activities. They can be simultaneously damaged by diseases of different aetiology, most frequently of immunologic, hereditary, infectious origin, or related to pregnancy, circulation and use of medical drugs; or a serious damage of one organ can be followed by subsequent damage of the other one. Liver failure in cirrhosis leads to acute kidney injury of prerenal aetiology, i.e. to the development of the hepatorenal syndrome. Its prognosis depends on the degree of liver damage. In type I hepatorenal syndrome, there is a rapid progression and worse prognosis as compared to type II. The primary renal illness can be followed by secondary liver damage due to toxic effect on liver tissue by hepatic clearance of drugs, e. g. antibiotics. Evaluation scores (MELD, Child-Pugh or King‘s College) have been developed for the most seriously ill patients with liver failure and kidney failure, allowing to enrol patients on priority positions in the waiting lists for liver or combined liver and kidney transplantation.

Key words:
liver function – kidney function – hepatorenal syndrome – liver and kidney transplantation

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted: 13. 5. 2018

Accepted: 1. 6. 2018

Zdroje

1. Filip K. Ledviny a játra. In: Teplan V. Metabolismus a ledviny. Praha: Grada 2000: 173–193.

2. Degos F, Grünefeld JP. Liver diseases and the kidney. In: Cameron S, Davison AM, Grünefeld JP. Oxford textbook of clinical nephrology. Volume III. Oxford: Oxford University Press 1992: 2312–2316.

3. Teplan V. Nefrologické minimum pro klinickou praxi. 2. vyd. Praha: Mladá fronta Aesculap 2017.

4. Mareček Z. Wilsonova choroba. Praha: Galén 1996.

5. Epstein M. The kidney in liver disease. 4^th ed. Philadelphia: Hanley & Belfus 1996.

6. Epstein M. Renal function in liver disease. In: Gilbert S, Weiner D. National Kidney Foundation‘s Primer on kidney diseases. 2nd ed. 1998: 188–193.

7. Teplan V. Akutní poškození a selhání ledvin v klinické medicíně. Praha: Grada 2010.

8. Ginès P, Arroyo V, Rodés J et al. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. 2nd ed. Malden: Wiley Blackwell Publish 2005: 341–359.

9. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361 (13): 1279–1290. doi: 10.1056/NEJMra0809139.

10. Arroyo V, Terra C, Tore C et al. Hepatorenal syndrome in cirrhosis: clinical features, diag-nosis and management. In: Ginès P, Arroyo V, Rodés J et al. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis, and treatment. 2nd ed. Malden: Wiley Blackwell Publish 2005: 341–359.

11. Lata J. Hepatorenal syndrome. World J Gastroenterol 2012; 18 (36): 4978–4984. doi: 10.3748/wjg.v18.i36.4978.

12. Horák J. Hepatorenální syndrom. In: Teplan V. Akutní poškození a selhání ledvin v klinické medicíně. Praha: Grada 2010: 263–270.

13. Hartleb M, Gutkowski K. Kidney in chron-ic liver diseases. World J Gastroenterol 2012; 18 (24): 3035–3049. doi: 10.3748/wjg.v18.i24.3035.

14. Devenport A. Management of acute kidney injury in liver disease. Contrib Nephrol 2010; 165: 197–205. doi: 10.1159/000313759.

15. KDIGO. Clinical practice guideline for acute kidney injury. Kidney Int Suppl 2012; 2 (1): 19–36.

16. Trunečka P. Hepatorenální poškození. In: Teplan V. Nefrologie vyššího věku. Praha: Mladá fronta 2015: 173–193.

17. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33 (2): 464–470.

18. Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60 (8): 646–649.

19. O‘Grady JG, Alexander GJ, Hayllar KM et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97 (2): 439–445.

20. Angeli P, Merkel C. Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis. J Hepatol 2008; 48 (Suppl 1): S93–S103. doi: 10.1016/j.jhep.2008.01.010.

21. Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009; 361 (13): 1279–1290. doi: 10.1056/NEJMra0809139.

22. Delanaye P, Cavalier E, Cristol JP et al. Calibration and precision of serum creatinine and plasma cystatin C measurement: impact on the estimation of glomerular filtration rate. J Nephrol 2014; 27 (5): 467–475. doi: 10.1007/s40620-014-0087-7.

23. Davenport A, Cholongitas E, Xirouchakis E et al. Pitfalls in assessing renal function in patients with cirrhosis – potential inequity for access to treatment of hepatorenal failure and liver transplantation. Nephrol Dial Transplant 2011; 26 (9): 2735–2742. doi: 10.1093/ndt/gfr354.

24. Wadei HM, Geiger XJ, Cortese C et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant 2008; 8 (12): 2618–2626. doi: 10.1111/j.1600-6143.2008.02426.x.

25. Dube GK, Cohen DJ. Simultaneous liver and kidney transplantation. Curr Opin Nephrol Hypertens 2007; 16 (6): 547–553.

26. Eason JD, Gonwa TA, Davis CL et al. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant 2008; 8 (11): 2243–2251. doi: 10.1111/j.1600-6143.2008.02416.x.